Elamipretide SS-31 CAS 736992-21-5 lyophilized peptide powder, cardiolipin-binding mitochondrial peptide

Elamipretide CAS 736992-21-5 SS-31 Cardiolipin-Binding Mitochondrial Peptide

Elamipretide (SS-31, MTP-131, Bendavia) CAS 736992-21-5, cardiolipin-binding mitochondrial tetrapeptide, lyophilized powder, ≥99% HPLC, store at -20°C, COA available for research use

Category: Tags: , , , , , , , , , , , ,
Elamipretide (SS-31, MTP-131, Bendavia) CAS 736992-21-5, cardiolipin-binding mitochondrial tetrapeptide, lyophilized powder, ≥99% HPLC, store at -20°C, COA available for research use.
Elamipretide CAS 736992-21-5 98% Purity SS-31 Peptide Powder - NutraBiotech

Elamipretide CAS 736992-21-5
SS-31 Cardiolipin-Binding Mitochondrial Peptide

Elamipretide (SS-31, MTP-131; CAS 736992-21-5) is a synthetic aromatic-cationic tetrapeptide, H-D-Arg-Dmt-Lys-Phe-NH2, that concentrates at the inner mitochondrial membrane and binds cardiolipin, supporting cristae architecture and electron-transport function. In September 2025 the same molecule became the first therapy granted accelerated approval by the US FDA for Barth syndrome, marketed there as FORZINITY following the TAZPOWER trial. It is also widely used as a research probe in primary mitochondrial myopathy, geographic atrophy, cardiology and senescence models. Formula C32H49N9O5, MW 639.78. Research grade, ≥98% HPLC, shipped with COA.

ElamipretideSS-31MTP-131CardiolipinInner Mitochondrial MembraneBarth SyndromeSzeto-Schiller PeptideOXPHOS
Request a Quote Technical Specs
639.78
MW (C32H49N9O5)
≥98%
Purity (HPLC)
2025
First indication approved

Molecular Information

Name: Elamipretide
CAS: 736992-21-5
Sequence: H-D-Arg-Dmt-Lys-Phe-NH2
Formula: C32H49N9O5
MW: 639.78 g/mol (free peptide)
[M+H]+: 640.393 (calculated)
Class: Aromatic-cationic tetrapeptide amide
Family: Szeto-Schiller (SS) peptide
Net charge: Positive at neutral pH
Target: Inner mitochondrial membrane cardiolipin
Appearance: White lyophilised powder
Storage: -20 °C, dry, protect from light
736992-21-5
🧪
CAS Number
639.78
⚖️
Molecular Weight
Cardiolipin
🎯
Binding Partner
≥98%
✅
Purity (HPLC)

Product Technical Specifications

Peptide identity, counter-ion handling and QC parameters for Elamipretide (CAS 736992-21-5)

📋 Peptide Identity

  • Product NameElamipretide
  • Peptide SequenceH-D-Arg-Dmt-Lys-Phe-NH2 (4 residues)
  • Systematic ResiduesD-arginyl-2′,6′-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
  • CAS Number736992-21-5
  • SynonymsElamipretide; SS-31; MTP-131; Bendavia; D-Arg-Dmt-Lys-Phe-NH2
  • US Brand (finished drug)FORZINITY
  • Non-standard ResidueDmt = 2′,6′-dimethyl-L-tyrosine
  • Terminal ModificationsN-terminal D-arginine; C-terminal amide
  • Molecular FormulaC32H49N9O5
  • Molecular Weight639.78 g/mol (free peptide basis)
  • Calculated [M+H]+640.393
  • PubChem CID11764719
  • FDA UNII87GWG91S09
  • AppearanceWhite lyophilised powder
  • SolubilityWater up to 100 mg/mL; DMSO ≥29 mg/mL
  • HS Code2937.19 (peptide classification; confirm per destination)

🔬 Quality Control & Handling

  • Purity (HPLC)≥98%
  • FormLyophilised powder in sealed vial
  • Identity ConfirmationMS to m/z 640.393 (formula level)
  • Stereochemistry CheckChiral amino-acid analysis (not resolvable by MS)
  • Binding PartnerCardiolipin, inner mitochondrial membrane
  • Typical ReadoutsOCR; ATP; cardiolipin content; ROS; mPTP; cytochrome c peroxidase
  • ReconstitutionSterile water, saline or bacteriostatic water; DMSO for organic stock
  • Counter-ionAcetate or TFA; net peptide content stated per lot
  • Storage (powder)-20 °C; -80 °C for longest term
  • Storage (in solution)Aliquot at -80 °C up to 6 months; avoid repeated freeze-thaw
  • ShippingCold chain recommended; ambient on request
  • QC DocumentationCOA / HPLC / MS / chiral analysis / MSDS
  • Pack Sizes100 mg / 1 g / 10 g / 100 g / 1 kg / 10 kg
  • Stock StatusIn Stock
  • Use StatementResearch use only; not a finished drug product

Key Molecular Targets & Pathway Nodes

Elamipretide engages the inner mitochondrial membrane lipid environment rather than a single enzyme.

🫀 Cardiolipin 🔋 Inner mitochondrial membrane 🧪 Cytochrome c ⚡ Electron transport complexes 🧬 ATP synthase / OXPHOS 🔥 Reactive oxygen species 🌀 Cristae architecture 🚪 Permeability transition pore 🧴 NLRP3 inflammasome 👁️ Photoreceptor ellipsoid zone

How Elamipretide Works: Repairing the Inner Mitochondrial Membrane

A three-stage process: selective accumulation, cardiolipin association, restoration of oxidative phosphorylation.

1

Accumulation at the Inner Membrane

The alternating aromatic and cationic residues plus the D-arginine and amidated C-terminus give the peptide a net positive charge and resistance to exopeptidases. Published work reports enrichment at the inner mitochondrial membrane several thousand-fold over cytosol, largely independent of membrane potential.

2

Association with Cardiolipin

Cardiolipin is the signature phospholipid of the inner mitochondrial membrane and the anchor for electron-transport supercomplexes. Elamipretide associates with cardiolipin and helps preserve cristae architecture and complex organisation under stress.

3

Restored Bioenergetics, Less Oxidative Leak

With membrane organisation preserved, electron flux and ATP synthesis recover, electron leak and reactive oxygen species fall, cardiolipin peroxidation is limited, cytochrome c peroxidase activity is suppressed and opening of the permeability transition pore is delayed.

⚖️ Elamipretide vs Comparator Tools

  • Elamipretide (this product)Cardiolipin-binding SS peptide
  • EpitalonTetrapeptide used in senescence research
  • Coenzyme Q10 / MitoQQuinone electron and redox carriers
  • IdebenoneSynthetic quinone redox agent
  • TUDCAMitochondrial and ER stress modulator
  • Selective EdgeTargets the membrane lipid rather than one redox step
  • Research NicheMitochondrial disease, cardiology, retinal models

♻️ Downstream Biological Consequences

  • CristaeArchitecture and curvature preserved
  • Electron transportSupercomplex organisation supported
  • ATPOxidative phosphorylation output supported
  • ROSMitochondrial emission reduced
  • CardiolipinPeroxidation limited
  • Cytochrome cPeroxidase activity suppressed
  • Cell deathPermeability transition pore opening delayed
  • InflammationNLRP3 inflammasome signalling dampened

Research & Formulation Applications

Elamipretide is used wherever mitochondrial bioenergetics, cardiolipin content or cristae integrity are the experimental endpoint.

🧬

Barth Syndrome & TAZ Models

Cardiolipin remodelling deficiency linked to TAZ variants; the setting behind the 2025 accelerated approval.

Barth / TAZ
💪

Primary Mitochondrial Myopathy

Muscle strength, endurance and oxygen consumption endpoints in PMM trial-derived models.

PMM
👁️

Retinal & Photoreceptor Models

Photoreceptor ellipsoid-zone preservation in geographic atrophy models and retinal ganglion cell work.

Ophthalmology
🫀

Cardiac Ischaemia & Failure

Reperfusion injury, infarct size and left ventricular function endpoints in ischaemia-reperfusion models.

Cardiology
🩸

Renal Injury Models

Ischaemic acute kidney injury; mitochondrial depolarisation, ATP recovery and tubular repair endpoints.

AKI
🧠

Bioenergetic Assay Development

Seahorse OCR panels, cardiolipin quantification, mPTP opening, mitochondrial ROS and membrane-potential assays.

Assays

Key Literature & Clinical Evidence

Mechanistic and clinical references covering the Szeto-Schiller peptide family and its translational track record.

Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
DOI: 10.1111/bph.12461
Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
Renal ischaemia reference
Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3):e238-e252.
DOI: 10.1212/WNL.0000000000207417
Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437.
DOI: 10.1016/j.cardfail.2020.01.005
Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303.
DOI: 10.1093/eurheartj/ehv597
Zhao W, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019;16(1):230.
DOI: 10.1186/s12974-019-1621-9
Stealth BioTherapeutics. FORZINITY (elamipretide) injection prescribing information. US Food and Drug Administration; revised September 2025.
Regulatory reference

Supply, IP & Compliance Notes

Regulatory position of the molecule and how this research material differs from the finished prescription product.

⚠️ Regulatory Position

  • First ApprovalUS FDA, 19 September 2025
  • Approval RouteAccelerated approval
  • Approved IndicationMuscle strength in Barth syndrome ≥30 kg
  • US Trade NameFORZINITY (elamipretide) injection
  • Approvals Outside USNone declared in trial documentation
  • This ListingBulk research material, not the drug product

📦 Post-Approval Commitments

  • Accelerated BasisKnee extensor strength (TAZPOWER)
  • Confirmatory Trial4TAZPower Phase 3b/4 (NCT07531251)
  • Trial StartFirst patient dosed mid-2026
  • DesignationsOrphan Drug; Fast Track; Priority Review; Rare Pediatric Disease
  • Pipeline AreasYounger Barth patients; nPMD; dry AMD
  • IP ConsiderationComposition and method patents held by originator

Available Sizes & Ordering

Research-grade Elamipretide (CAS 736992-21-5) with full QC documentation; supplied from 100 mg research packs through to 10 kg production batches.

TierPack SizeStock StatusSuitable ForLead Time
Research100 mgIn StockCellular OCR, ROS and mPTP assaysSame/next-day ship
Standard1 gIn StockExtended in vitro panelsSame/next-day ship
Scale-up10 gIn StockIn vivo dose-ranging and formulation screening3–5 business days
Pilot100 gMade to orderProcess development and pilot batchesQuote to confirm
Commercial1 kgMade to orderContract supply and validation runsBatch delivery
Industrial10 kgMade to orderLarge-scale production schedulingReserved batch slot

Reference sizes shown above; for exact pricing and availability please contact us for a quote. Bulk orders qualify for tiered discounts.

Frequently Asked Questions (FAQ)

What is elamipretide and what is it researched for?
Elamipretide, also written SS-31 or MTP-131 (CAS 736992-21-5), is a synthetic aromatic-cationic tetrapeptide with the sequence H-D-Arg-Dmt-Lys-Phe-NH2. It is investigated wherever mitochondrial dysfunction is the experimental focus: Barth syndrome and TAZ-deficient models, primary mitochondrial myopathy, geographic atrophy, myocardial ischaemia-reperfusion injury, acute kidney injury, neuroinflammation and senescence models. Molecular formula C32H49N9O5, molecular weight 639.78.
What does Dmt mean in the sequence?
Dmt is 2′,6′-dimethyl-L-tyrosine, a non-standard residue carrying two methyl groups on the aromatic ring. It adds carbon and hydrogen mass relative to plain tyrosine, which is why the tetrapeptide is C32H49N9O5 rather than C30H45N9O5. Together with the N-terminal D-arginine and the amidated C-terminus it raises stability against exopeptidases and lowers susceptibility to enzymatic degradation.
How does elamipretide affect mitochondrial function?
The peptide associates with cardiolipin, the signature phospholipid of the inner mitochondrial membrane. Published work describes preserved cristae architecture, better organisation of electron-transport supercomplexes, improved ATP output, lower reactive oxygen species emission, reduced cardiolipin peroxidation, suppression of cytochrome c peroxidase activity and delayed opening of the permeability transition pore.
Is elamipretide an approved medicine?
In the United States the finished product FORZINITY (elamipretide) injection received accelerated approval on 19 September 2025 for improving muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg. No approval outside the United States is declared in trial documentation. The material listed on this page is bulk research-grade active intended for laboratory use and is not the finished prescription product.
What supported the 2025 accelerated approval?
Approval rested on improvement in knee extensor muscle strength, an intermediate clinical endpoint from the randomised, double-blind, placebo-controlled TAZPOWER trial (NCT03098797). Continued approval depends on verification of clinical benefit, and a confirmatory Phase 3b/4 post-marketing trial, 4TAZPower (NCT07531251), began dosing participants during 2026.
How soluble is elamipretide and how are working solutions prepared?
Elamipretide is freely soluble in water, reported up to 100 mg/mL, and also soluble in DMSO at 29 mg/mL or above. Reconstitute the lyophilised powder with sterile water, physiological saline or bacteriostatic water for aqueous work, or with fresh DMSO for an organic stock, then dilute into buffer immediately before use. Aliquot and freeze to avoid repeated freeze-thaw cycling.
How should lyophilised elamipretide be stored?
Store the sealed vial dry at -20 °C protected from light, with -80 °C preferred for retention over multiple years. Reported figure ranges differ between suppliers, from about one year at -20 °C to longer periods under deeper cold, so the lot-specific retest date on the certificate of analysis governs practice. Reconstituted solutions are aliquoted and held at -80 °C for up to six months.
Why is chiral amino-acid analysis included in the QC set?
D-arginine and L-arginine have identical mass, so mass spectrometry confirms the formula C32H49N9O5 through the calculated ion at m/z 640.393 but cannot establish the configuration at that position. Chiral amino-acid analysis is therefore required to verify that the first residue really is D-arginine rather than the natural L-form, and it is reported as a separate item on the certificate of analysis.
Is the peptide supplied as free base or as a salt?
Elamipretide carries three basic sites, the N-terminal amine, the arginine guanidine and the lysine side-chain amine, so isolated material pairs with counter-ions. Research material is commonly supplied as an acetate or trifluoroacetate salt, and each lot is released with the net peptide content and counter-ion stated on the certificate of analysis so that molar calculations use the peptide fraction rather than the salt mass.
What QC documentation ships with each lot?
Each lot ships with a certificate of analysis reporting HPLC purity, mass-spectrometric identity confirmation, chiral amino-acid analysis for the D-arginine configuration, net peptide content and counter-ion. MSDS or SDS is available on request.
Which pack sizes are available and is bulk supply supported?
Elamipretide is offered in six standard sizes: 100 mg, 1 g, 10 g, 100 g, 1 kg and 10 kg. The 100 mg, 1 g and 10 g sizes are held in stock, while 100 g, 1 kg and 10 kg are made to order against a quotation. Bulk quantities qualify for tiered discounts, and lead time is quoted per batch.
Which related research peptides are available?
Related material includes Epitalon, another short peptide used in cellular senescence work, and TUDCA for mitochondrial and endoplasmic-reticulum stress models. The full list sits under the peptides category.

Need Elamipretide for Your Research?

Research-grade Elamipretide (CAS 736992-21-5) — purity ≥98% HPLC, COA included
SS-31 cardiolipin-binding mitochondrial peptide — request a quote today

Request a Quote →

Elamipretide (CAS 736992-21-5) listed here is bulk research-grade material supplied for laboratory research use only. It is not the finished prescription product FORZINITY, not a dietary ingredient, and not intended to diagnose, treat, cure or prevent any disease. The finished drug is approved in the United States for Barth syndrome in patients weighing at least 30 kg and is not declared as approved elsewhere. Composition and method patents are held by the originating organisation, and patent status should be confirmed for the intended territory before any commercial activity.

Related products